What is the difference between MOTS-C and SS-31 (Elamipretide)?

The main difference is mechanism and research stage. MOTS-C targets Mitochondrial-derived peptide (preclinical / early research) and is studied for metabolism & insulin-sensitivity research; SS-31 (Elamipretide) targets Cardiolipin-binding tetrapeptide (investigational) and is studied for mitochondrial-function research. Both are research-use-only compounds, not for human or animal use.

Are MOTS-C and SS-31 (Elamipretide) approved for human use?

No. Renova Wellness supplies both strictly for in-vitro laboratory and scientific research use only. Research status differs — MOTS-C: preclinical / early research; SS-31 (Elamipretide): investigational — but neither is sold for human or animal consumption, and no medical, therapeutic, or dosing claims are made.

How is purity verified for MOTS-C and SS-31 (Elamipretide)?

Every lot of both compounds ships with its own per-batch Certificate of Analysis — identity by mass spectrometry, ≥98% purity by HPLC, and a unique lot number you can verify against the vial in your hand.

Research Comparison

MOTS-C vs SS-31 (Elamipretide)

MOTS-C and SS-31 (Elamipretide) are often compared because both sit in mitochondrial research. MOTS-C acts on mitochondrial-derived peptide and is studied for metabolism & insulin-sensitivity research, while SS-31 (Elamipretide) acts on cardiolipin-binding tetrapeptide and is studied for mitochondrial-function research. Both are supplied as lyophilized powder for in-vitro laboratory research only — this page compares mechanism and research status, not dosing or human use.

MOTS-C

Mitochondrial

SS-31 (Elamipretide)

Mitochondrial

Frequently asked

What is the difference between MOTS-C and SS-31 (Elamipretide)?: The main difference is mechanism and research stage. MOTS-C targets Mitochondrial-derived peptide (preclinical / early research) and is studied for metabolism & insulin-sensitivity research; SS-31 (Elamipretide) targets Cardiolipin-binding tetrapeptide (investigational) and is studied for mitochondrial-function research. Both are research-use-only compounds, not for human or animal use.
Are MOTS-C and SS-31 (Elamipretide) approved for human use?: No. Renova Wellness supplies both strictly for in-vitro laboratory and scientific research use only. Research status differs — MOTS-C: preclinical / early research; SS-31 (Elamipretide): investigational — but neither is sold for human or animal consumption, and no medical, therapeutic, or dosing claims are made.
How is purity verified for MOTS-C and SS-31 (Elamipretide)?: Every lot of both compounds ships with its own per-batch Certificate of Analysis — identity by mass spectrometry, ≥98% purity by HPLC, and a unique lot number you can verify against the vial in your hand.

Key research terms

MOTS-C guide SS-31 (Elamipretide) guide Half-Life Reconstitution Research Use Only (RUO)

Related comparisons

MOTS-C vs Tesamorelin

Build a multi-compound set in the Stack Builder or run the reconstitution calculator.

Research references

Primary literature for MOTS-C and SS-31 (Elamipretide). Provided for scientific context only — not medical or dosing guidance.

Lee C, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015. PMID 25738459 →
Reynolds JC, et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nat Commun. 2021. PMID 33473109 →
Pharaoh G, et al. The mitochondrially targeted peptide elamipretide (SS-31) improves ADP sensitivity in aged mitochondria. Geroscience. 2023. PMID 37462785 →
Mitchell W, et al. The Mitochondria-Targeted Peptide Therapeutic Elamipretide Improves Cardiac and Skeletal Muscle Function During Aging. Aging Cell. 2025. PMID 40080911 →

Research use only. This comparison covers mechanism, target, and research status. It is not medical, therapeutic, or dosing advice. Compounds sold by Renova Wellness™ are for in-vitro laboratory research and are not for human or animal consumption.